首页> 外文期刊>Antimicrobial agents and chemotherapy. >The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri
【24h】

The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri

机译:重组噬菌体鼻塞素Hy-133对葡萄球菌综合体的不同非洲克隆谱系具有体外活性,包括葡萄球菌施韦利松

获取原文
获取原文并翻译 | 示例
           

摘要

HY-133 is a recombinant bacteriophage endolysin with bactericidal activity against Staphylococcus aureus. Here, HY-133 showed in vitro activity against major African methicillin-susceptible and methicillin-resistant S. aureus lineages and ceftaroline/ceftobiprole- and borderline oxacillin-resistant isolates. HY-133 was also active against Staphylococcus schweitzeri, a recently described species of the S. aureus complex. The activity of HY-133 on the tested isolates (MIC50, 0.25 mu g/ml; MIC90, 0.5 mu g/ml; range, 0.125 to 0.5 mu g/ml) was independent of the species and strain background or antibiotic resistance.
机译:Hy-133是一种重组噬菌体鼻内蛋白,其含有抗氧化葡萄球菌的杀菌活性。 这里,Hy-133显示对主要非洲甲氧西林的体外活性,易受易甲氧西林的金黄色葡萄球菌和Ceftarline / CeftobroLe和邻近羟基虫蛋白抗性分离物的体外活性。 Hy-133也活跃于葡萄球菌综合体的最近描述的物种。 在测试的分离株(MIC50,0.25μg/ ml;MIC90,0.5μg/ ml;范围,0.125至0.5μg/ ml)的活性与物种和应变背景或抗生素抗性无关。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号